Drug intelligence / Profile preview

BP-006

Development stage: Preclinical
Lead developer: Brillian Pharma
Modality: Small Molecules
Administration: Oral

Overview

BP-006 is an extended-release (ER) pediatric formulation developed by Brillian Pharma using its proprietary Unidose technology. The product is designed as a lyophilized oral suspension, intended to provide a child-friendly, single-dose format for an existing medication. Brillian Pharma specializes in the reformulation of established drugs to improve pediatric compliance, safety, and ease of administration. While the specific active pharmaceutical ingredient for BP-006 is not disclosed in public pipeline documents, it is categorized as an ER formulation asset designed to provide sustained drug release, potentially reducing the frequency of administration for pediatric patients.

Other names: BP-006 ER Unidose suspensionBP006 ER Unidose suspensionBP 006 ER Unidose suspension

Beyond the preview

Go deeper on BP-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP-006.

Explore the full profile